Xbrane completes enrollment in pivotal nivolumab biosimilar trial

Eight out of twelve patients with B-cell lymphoma and no remaining curative treatment options achieved a complete metabolic response after treatment with Elicera Therapeutics’ ELC-301. The results come from the now-completed Phase I part of the Swedish CARMA study.

Zealand Pharma's amylin analog petrelintide produced up to 9.2% mean weight loss after 28 weeks in people with overweight or obesity and type 2 diabetes, compared with 2.0% on placebo, in the Phase 2 ZUPREME-2 trial.

Oncopeptides’ peptide drug conjugate crossed the blood-brain barrier in the first three patients treated in a glioblastoma study at Oslo University Hospital. Drug concentrations in the tumors matched preclinical models.

Stockholm-based Pharmability has dosed the first patient in its Phase Ib study of TIR-C in atopic dermatitis, and the first cohort is now fully enrolled. The trial is the first in which the drug candidate is tested in humans.

Genmab and AbbVie's bispecific antibody epcoritamab, added to standard R-CHOP chemoimmunotherapy, significantly improved progression-free survival in the Phase III EPCORE DLBCL-2 trial in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The companies say it is the first Phase III study of a bispecific antibody combination to show such a benefit in the frontline setting.

Boehringer Ingelheim's survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.

Lundbeck has randomized the first patient in the Phase II DARE2 trial of its oral Parkinson's candidate Lu AF28996. In an interview with NLS, Tarek Samad, Head of R&D, explains what the trial needs to show to justify Phase III and where the drug could fit alongside existing treatments.